Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Phase 3

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: IV Tulisokibart
Drug: SC Tulisokibart
Drug: IV Placebo
Drug: SC Placebo

First Posted Date: 2023-09-25

Last Posted Date: 2025-05-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1020

Registration Number: NCT06052059

Locations: 🇯🇵
Sapporohigashi Tokushukai Hospital ( Site 2860), Sapporo, Hokkaido, Japan
🇯🇵
Hyogo Medical University Hospital ( Site 2830), Nishinomiya, Hyogo, Japan
🇯🇵
Hitachi General Hospital ( Site 2856), Hitachi, Ibaraki, Japan

and more 420 locations

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Phase 1

Completed

Conditions: Non-alcoholic Steatohepatitis
Hepatic Impairment

Interventions: Drug: Efinopegdutide

First Posted Date: 2023-09-25

Last Posted Date: 2024-12-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 22

Registration Number: NCT06052566

Locations: 🇺🇸
Clinical Pharmacology of Miami ( Site 0005), Miami, Florida, United States
🇺🇸
American Research Corporation ( Site 0002), San Antonio, Texas, United States
🇺🇸
Advanced Pharma CR, LLC ( Site 0001), Miami, Florida, United States

and more 1 locations

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Phase 1

Active, not recruiting

Conditions: Programmed Cell Death-1 (PD1, PD-1)
Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
Solid Tumors
Non-small Cell Lung Cancer
Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Interventions: Biological: Sacituzumab tirumotecan
Biological: Pembrolizumab

First Posted Date: 2023-09-22

Last Posted Date: 2025-05-31

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 36

Registration Number: NCT06049212

Locations: 🇯🇵
Aichi Cancer Center Hospital ( Site 0006), Nagoya, Aichi, Japan
🇯🇵
National Cancer Center Hospital East ( Site 0002), Kashiwa, Chiba, Japan
🇯🇵
National Hospital Organization Shikoku Cancer Center ( Site 0008), Matsuyama, Ehime, Japan

and more 4 locations

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

Phase 2

Completed

Conditions: HIV
HIV Pre-exposure Prophylaxis

Interventions: Drug: Placebo to MK-8527
Drug: MK-8527

First Posted Date: 2023-09-21

Last Posted Date: 2025-03-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 352

Registration Number: NCT06045507

Locations: 🇺🇸
University of Pittsburgh Medical Center-Division of Infectious Diseases ( Site 0041), Pittsburgh, Pennsylvania, United States
🇿🇦
Wits RHI-Wits RHI Ward 21 Clinical Research site ( Site 0027), Johannesburg, Gauteng, South Africa
🇿🇦
Helen Joseph Hospital ( Site 0024), Johannesburg, Gauteng, South Africa

and more 15 locations

A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Phase 2

Recruiting

Conditions: Squamous Cell Carcinoma

Interventions: Biological: Pembrolizumab (+) Berahyaluronidase alfa

First Posted Date: 2023-09-18

Last Posted Date: 2025-05-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 19

Registration Number: NCT06041802

Locations: 🇯🇵
Wakayama Medical University Hospital ( Site 0015), Wakayama, Japan
🇯🇵
Nagoya University Hospital ( Site 0003), Nagoya, Aichi, Japan
🇯🇵
Sapporo Medical University Hospital ( Site 0002), Sapporo, Hokkaido, Japan

and more 12 locations

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Phase 2

Active, not recruiting

Conditions: Cutaneous Squamous Cell Carcinoma
Endometrial Cancer
Solid Tumor

Interventions: Biological: favezelimab/pembrolizumab
Biological: pembrolizumab
Drug: lenvatinib

First Posted Date: 2023-09-14

Last Posted Date: 2025-03-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 160

Registration Number: NCT06036836

Locations: 🇺🇸
Yale-New Haven Hospital-Yale Cancer Center ( Site 0643), New Haven, Connecticut, United States
🇺🇸
Dana-Farber Cancer Institute ( Site 0642), Boston, Massachusetts, United States
🇺🇸
Rutgers Cancer Institute of New Jersey ( Site 0635), New Brunswick, New Jersey, United States

and more 41 locations

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Phase 3

Recruiting

Conditions: Arteriosclerosis
Hypercholesterolaemia

Interventions: Drug: Enlicitide Decanoate
Drug: Placebo

First Posted Date: 2023-08-24

Last Posted Date: 2025-06-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 14550

Registration Number: NCT06008756

Locations: 🇭🇰
Queen Mary Hospital-Medical ( Site 3300), Pok Fu Lam, Hong Kong
🇮🇱
Linn Medical Center ( Site 1711), Haifa, Israel
🇺🇸
Advanced Cardiovascular - Alexander City ( Site 0156), Alexander City, Alabama, United States

and more 664 locations

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: MK-5720
Drug: Placebo to MK-5720
Drug: MK-8189
Drug: Placebo to MK-8189

First Posted Date: 2023-07-20

Last Posted Date: 2025-03-04

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 17

Registration Number: NCT05953740

Locations: 🇺🇸
California Clinical Trials Medical Group managed by PAREXEL ( Site 0003), Glendale, California, United States
🇺🇸
Velocity Clinical Research, Hallandale Beach ( Site 0002), Hallandale Beach, Florida, United States
🇺🇸
Hassman Research Institute Marlton Site ( Site 0007), Marlton, New Jersey, United States

and more 1 locations

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH

Phase 3

Completed

Conditions: Hypercholesterolemia
Familial Hypercholesterolemia

Interventions: Drug: Placebo
Drug: Enlicitide Decanoate

First Posted Date: 2023-07-19

Last Posted Date: 2025-05-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 303

Registration Number: NCT05952869

Locations: 🇸🇬
National University Hospital-Department of Medicine ( Site 3212), Singapore, Central Singapore, Singapore
🇺🇸
Velocity Clinical Research at The Pioneer Heart Institute, Lincoln ( Site 0026), Lincoln, Nebraska, United States
🇧🇷
Incor - Instituto do Coracao ( Site 0703), Sao Paulo, Brazil

and more 56 locations

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

Phase 3

Active, not recruiting

Conditions: Hypercholesterolemia
Familial Hypercholesterolemia

Interventions: Drug: Enlicitide Decanoate
Drug: Placebo

First Posted Date: 2023-07-19

Last Posted Date: 2024-11-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 2760

Registration Number: NCT05952856

Locations: 🇺🇸
Midwest Institute For Clinical Research ( Site 0059), Indianapolis, Indiana, United States
🇺🇸
Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0111), Houston, Texas, United States
🇹🇷
Ege Universitesi Hastanesi-Cardilogy Department ( Site 2502), Bornova, Izmir, Turkey

and more 165 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy